Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group - Scorecard - MDSpire
Advertisement
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
Clinical Scorecard: Comparison of Whole-Body CT and Traditional Skeletal Surveys in Patients Diagnosed with Multiple Myeloma: Insights from the International Myeloma Working Group Study
At a Glance
Category
Detail
Condition
Multiple Myeloma with bone disease
Key Mechanisms
Detection of lytic bone lesions using imaging modalities; WBCT provides three-dimensional imaging with higher sensitivity than conventional skeletal surveys (CSS)
Target Population
Patients with histologically proven multiple myeloma, including smoldering multiple myeloma
Care Setting
Multicenter international clinical and radiological diagnostic settings
Key Highlights
Conventional skeletal survey (CSS) has limited sensitivity, detecting bone damage only after 30–50% bone mass destruction.
Whole-body CT (WBCT) is significantly more sensitive than CSS for detecting lytic bone lesions in multiple myeloma.
WBCT detected additional lesions not seen on CSS in 25.5% of patients, with statistically significant higher detection odds (OR 4.50; P<0.0001).
Guideline-Based Recommendations
Diagnosis
Use WBCT as a more sensitive imaging modality for detecting skeletal lesions in multiple myeloma.
Apply IMWG updated guidelines incorporating modern cross-sectional imaging techniques including WBCT.
Management
Consider WBCT findings in disease staging and treatment decisions, acknowledging the higher sensitivity may detect earlier lesions.
Monitoring & Follow-up
Perform imaging studies (WBCT and/or CSS) within a short interval (e.g., 30 days) for accurate disease assessment.
Use consensus reading by experienced radiologists blinded to clinical data to reduce bias.
Risks
Be cautious of overdiagnosis due to WBCT detecting lesions that may not yet be clinically relevant.
Balance radiation exposure with diagnostic benefit; WBCT uses low-dose protocols optimized for skeletal imaging.
Patient & Prescribing Data
212 patients with multiple myeloma (including 66 with smoldering myeloma), 159 untreated at imaging time
Additional lesions detected by WBCT may influence earlier diagnosis and treatment initiation, but prognostic relevance requires further evaluation.
Clinical Best Practices
Perform WBCT and CSS imaging within a 30-day window to allow direct comparison.
Use standardized lesion classification categories ('definitely present', 'probably present', etc.) for consistent reporting.
Interpret imaging results in multidisciplinary consensus to guide clinical decisions.
Recognize limitations of CSS in detecting early bone lesions and consider WBCT for comprehensive skeletal assessment.
by J Hillengass, L A Moulopoulos, S Delorme, V Koutoulidis, J Mosebach, T Hielscher, M Drake, S V Rajkumar, B Oestergaard, N Abildgaard, M Hinge, T Plesner, Y Suehara, K Matsue, N Withofs, J Caers, A Waage, H Goldschmidt, M A Dimopoulos, S Lentzsch, B Durie, E Terpos
For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.
